Breaking News

AMPAC Fine Chemicals Expands Capacity

March 21, 2016

Brings new capacity on-line to meet business growth

AMPAC Fine Chemicals (AFC) revealed their ongoing facilities expansion both in Rancho Cordova, CA and La Porte, TX has served to increase total capacities by 50% since 2013. AFC reports the most recent high potency facility—Semi-Works #4—is fully operational and they have started construction of a large-scale facility that will come on-line in late 2016.

“AFC is witnessing robust customer demand for our core technologies combined with our development and manufacturing expertise to support drug candidate maturation from clinical trials into commercial production,” said Aslam Malik, chief executive officer, AMPAC Fine Chemicals. “To meet this demand, we are investing over $40 million in 2016 for capacity expansion and infrastructure enhancements.”

The company reports the new facilities add nine reactors—500-2000 gal—Heinkel Hastelloy (HF-800) centrifuges plus additional solids handing and processing equipment necessary to support on-going production of cGMP intermediates and APIs.

“These two facilities benefit from AFC’s extensive experience in elimination of Foreign Object & Debris (FOD) and containment of potent compounds,” said Joseph Campbell, vice president of operations and engineering, AMPAC.
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials